Rhenium-186 HEDP: Palliative Radionuclide Therapy of Painful Bone Metastases: Preliminary results

References

• Blake G M, Zivanovic M A, McEvan A J, Ackery D M. Sr‐89 therapy: strontium kinetics in disseminated carcinoma of the proste. Eur J Nucl Med 1986; 12: 447–454
   PubMedGoogle Scholar
• Buchali K, Correns H J, Schuerer M, Schnorr D, Lips H, Sydow K. Results of a double blind study of strontium‐89 therapy of skeletal metastases of prostatic carcinoma. Eur J Nucl Med 1988; 14: 349–351
   PubMedGoogle Scholar
• De Klerk J MH, van Dijk A, van het Schip A D, Zonnenberg B A, van Rijk P P. Pharnacokinetics of rhenium‐186 after administration of rhenium‐186‐HEDP to patients with bone metastases. J Nucl Med 1992; 33: 646–651
   PubMed Web of Science ®Google Scholar
• De Klerk J MH, Zonnenberg B A, van het Schip A D, et al. Dose escalation study of rhenium‐186 hydroxyethyl‐idene diphophonate in patients with metastatic prostate cancer. Eur J Nucl Med 1994; 21: 1114–1120
   PubMedGoogle Scholar
• De Klerk J MH, van het Schip A D, Zonneberg B A. Evaluation of thrombocytopenia in patients treated with rhenium‐186 HEDP: guidlines for individual dosage recomrnondation. J Nucl Med 1994; 35: 1423–1428
   PubMed Web of Science ®Google Scholar
• Epstein L M, Stewart B H, Antunez A R. Half and total radiation for carcinoma of the prostate. J Urol 1979; 122: 330–333
   PubMed Web of Science ®Google Scholar
• Eisenhut M. Preparation of Re‐186 perrhenate for nuclear medical purpus. Int J Appl Radiat Isot 1982; 33: 99–103
   PubMedGoogle Scholar
• Firusian N, Mellin P, Schmidt C G. Results of strontium‐89 therapy in patients with carcinoma to the prostate and incurable pain from bone metastases: a preliminary report. J Urol 1976; 116: 764–768
   PubMed Web of Science ®Google Scholar
• Haesner M, Buchali K, Pink V, Lips H. Die Wirksam‐keit der Therapie niit 89Sr‐Strontiumchlorid bei 200 Patienten mit Skelettmetastasen eines Prostatakar‐zinoms. Nukleannedizin 1002; 31: 48–52
   Google Scholar
• Keen C W. Half body radiotherapy in the management of metastatic adenocarcinoma of the prostate. J Urol 1980; 123: 713–715
   PubMed Web of Science ®Google Scholar
• Kuban D A, Delbridge T, El‐Mahdi M. Half body irradiation for treatment of widely metastatic adenocarcinoma of the prostate. J Urol 1989; 141: 572–575
   PubMed Web of Science ®Google Scholar
• Laing A H, Ackery D M, Bayly R J, et al. Strontium‐89 cloride for pain palliation in prostate skeletal malignancy. Br J Urol 1991; 64: 816–822
   Google Scholar
• Maxon H R, Schroder L E, Hertzzberg V S. Rhenium 186–HEDP for treatment of painful osseous metastases: results of a double blind cross over comparison with placebo. J Nucl Med 1991; 32: 1877–1881
   PubMed Web of Science ®Google Scholar
• Maxon H R, Thomas S R, Hertzberg V S. Rhenium‐186 HEDP for the treatment of painful osseous metastases. Semin Nucl Med 1992; 22: 33–40
   PubMed Web of Science ®Google Scholar
• McEvan A J, Porter A T, Venner P M, Amyotte G. An evaluation of the safety and efficacy of the treatment with strontium‐89 in patients who have previously received wide field radiotherapy. Antibod Immunoconj Radiopharmacol 1990; 3: 91–98
   Google Scholar
• McEwan A J, Amyotte G A, McGowan D G, MacGilli‐vary J A, Porter A T. A retrospective analysis of the cost effectiveness of treatment with Metastron in patients with prostate cancer metastatic to bone. Eur Urol (Suppl) 1994; 26: 26–31
   PubMed Web of Science ®Google Scholar
• Muller St, Rembrink K, Reiners Chr. Die nuklearmedi‐zinische Schmerztherapie beim ossar metastasierten Prostatakarzinom. Urol Ausg A 1993; 32: 121–127
   PubMedGoogle Scholar
• Porter A T, McEvan A J, Powe J E, et al. Results of a randomized phase‐III trial to evaluate the efficancy of strontium‐89 adjuvant to local field external beam irradiation in the management of endrocrine resiteant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 1993; 25: 805–813
   PubMed Web of Science ®Google Scholar
• Porter A T. Strontium‐89 (Metastron) in the treatment of prostate cancer metastatic to bone. Eur Urol (Suppl) 1994; 26: 20–25
   PubMed Web of Science ®Google Scholar
• Robinson R G, Spicer J A, Preston D F, Wegst A V, Martin N L. Treatment of metastati bone p & with strontium‐89. Int J Radiat Appl Instrum B 1987; 14: 219–222
   PubMedGoogle Scholar
• Robinson R G, Blake G M, Preston D F, et al. Strontium‐89: treatment results and kinetics in patients with painful metastatic prostate and breast cancer. Radiographics 1989; 9: 271–281
   PubMedGoogle Scholar
• Robinson R G, Preston D F, Spicer J A, Baxter K G. Radionuclide therapy of intractable bone pain: emphasis on strontium‐89. Semin Nucl Med 1992; 22: 28–32
   PubMed Web of Science ®Google Scholar
• Robinson R G, Preston D F, Schiefelbein M, Baxten K G. Strontium 89 therapy for palliation of pain due to osseous metastases. JAMA 1995; 274: 429–434
   Web of Science ®Google Scholar
• Rowland C G, Bullimore J A, Smith P JB. Half body irradiation in the treatment of metastatic prostatic carcinoma. Br J Urol 1981; 53: 628–631
   PubMedGoogle Scholar
• Salzar O M, Rubin P, Hendrickson F R. Single bone half‐body irradiation for palliation of multiple bone metastases from solid tumors: final Radiation Oncology Group report. Cancer 1986; 58: 29–36
   PubMed Web of Science ®Google Scholar
• Tong D, Gillick L, Hendrikson F R. The palliation of symptomatic osseous metastases: final results of the study by the radiation Therapy Oncology Group. Cancer 1982; 30: 893–899
   Google Scholar
• Zonnenberg B A, De Klerk H JM, van Rijk P P. Re‐186 HEDP for treatment of painful bone metastases in patients with metastatic prostate or breast cancer. J Nucl Med 1991; 32: 1082–1091
   Google Scholar